SCHEMBL3107424

SCHEMBL3107424

CCNC(=O)c1ccc(-n2nnc(C(=O)O)c2-c2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.57
ALDH1A1 P00352 3/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2C9 P11712 1/20 0.57
HPGD P15428 1/20 0.57
CYP2C19 P33261 1/20 0.57
RECQL P46063 1/20 0.57
GAA P10253 1/20 0.51
POLB P06746 1/20 0.49
CA1 P00915 6/20 0.48
CA2 P00918 6/20 0.48
CA4 P22748 6/20 0.48
CA9 Q16790 6/20 0.48
HTT P42858 1/20 0.46
TP53 P04637 2/20 0.45
MAPT P10636 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PDE2A O00408 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3118300 0.86 ALDH1A1 (0.50) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL3115255 0.85 CA1 (0.61) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL13158528 0.83 HTT (0.61) ALDH1A1CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL3113646 0.81 HPGD (0.49) ALDH1A1CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL3115976 0.81 CYP1A2 (0.47) ALDH1A1CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL3109619 0.81 HPGD (0.48) ALDH1A1CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL4487634 0.80 KDM4E (0.72) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL3107039 0.80 CYP1A2 (0.47) ALDH1A1CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL3107047 0.80 CYP1A2 (0.47) ALDH1A1CYP1A2CYP2C9HPGDCYP2C19
SCHEMBL3109208 0.80 CYP1A2 (0.46) ALDH1A1CYP1A2CYP2C9HPGDCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
EP-1867331-A1 TRIAZOLE DERIVATIVE AND THE USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 KDM4E 3414/4885ALDH1A1 3580/4885CYP1A2 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.